ALAMEDA, Calif. -- (BUSINESS WIRE) -- Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced multiple presentations at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference to be held February 9-14 in San Francisco, California.
Alan Wu, M.D., Professor, Laboratory Medicine, University of California, San Francisco and Chief, Clinical Chemistry Laboratory at San Francisco General Hospital, will provide a keynote introductory address entitled, “The Power of Digital Detection to Establish Clinically Relevant Biomarkers.” Dr. Wu’s presentation will highlight the importance of detecting low-abundance biomarkers, such as proteins, in order to improve clinical diagnostics.
“In a world where protein assay innovation has not advanced tremendously over the years, the elegant SMC technology behind Singulex’s innovative biomarkers enables greater analytic sensitivity to detect minor increments above normal protein levels. This applies to a variety of diseases and can be especially relevant in cancer detection, where early detection using a highly sensitive biomarker can lead to earlier initiation of therapy and improved clinical outcomes,” said Dr. Wu. “High sensitivity protein assays provide improved precision which translates into increased clinical utility.”
Also at the conference, Lynn Zieske, Ph.D., Principal Scientist, Life Sciences at Singulex will deliver an oral presentation entitled “Quantitative Measurement of Low-Abundance Biomarkers Using Digital Single Molecule Counting,” and present a poster entitled “Use of the Erenna® Immunoassay Platform to Detect Pro-Inflammatory Cytokines in an in vitro Cytokine Release Assay.”
“During drug development, the ability to detect and quantify low-abundance biomarkers enables researchers to gain greater understanding of therapeutic safety and efficacy,” said Dr. Zieske. “As an example, monoclonal antibody-based therapeutics can cause cytokine release and unwanted side-effects. With the Erenna Immunoassay system and its ability to measure both baseline and elevated levels, researchers can gain early insight into such toxicities.”
The 2014 Molecular Medicine Tri-Conference will be held at the Moscone North Convention Center in San Francisco.
Presentations of interest include:
Dr. Zieske Oral Presentation
Quantitative Measurement of Low-Abundance Biomarkers Using Digital Single Molecule Counting, Lynn R. Zieske, Ph.D, et al
Monday, February 10th from 4:20 – 4:35pm
Dr. Wu Oral Presentation
The Power of Digital Detection to Establish Clinically Relevant Biomarkers
Monday, February 10th from 5:00 – 5:10pm
Dr. Zieske Poster Presentation
Use of the Erenna® Immunoassay Platform to Detect Pro-Inflammatory Cytokines in an in vitro Cytokine Release Assay, Lynn R. Zieske, Ph.D, et al
Monday, February 10th – Wednesday, February 12th
For conference information, please visit http://www.triconference.com/
About Singulex’s Erenna Platform
Powered by Single Molecule Counting (SMC™) technology, Singulex’s Research-Use-Only Erenna® Immunoassay System’s ability to measure small changes in biomarkers such as cardiac troponin I and cytokines, and to monitor these changes over time, has expanded the clinical utility of established markers. The Erenna system helps power the discovery and development of innovative lab developed tests and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis and diabetes.
About Singulex, Inc.
Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.
Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.